Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Design and Synthesis of Clinical Candidate PF-06751979: A Potent, Brain Penetrant, β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor Lacking Hypopigmentation.

O'Neill BT, Beck EM, Butler CR, Nolan CE, Gonzales C, Zhang L, Doran SD, Lapham K, Buzon LM, Dutra JK, Barreiro G, Hou X, Martinez-Alsina LA, Rogers BN, Villalobos A, Murray JC, Ogilvie K, LaChapelle EA, Chang C, Lanyon LF, Steppan CM, Robshaw A, Hales K, Boucher GG, Pandher K, Houle C, Ambroise CW, Karanian D, Riddell D, Bales KR, Brodney MA.

J Med Chem. 2018 May 24;61(10):4476-4504. doi: 10.1021/acs.jmedchem.8b00246. Epub 2018 Apr 17.

PMID:
29613789
2.

Unintended consequences of local alcohol restrictions in rural Alaska.

Ogilvie KA.

J Ethn Subst Abuse. 2018 Jan-Mar;17(1):16-31. doi: 10.1080/15332640.2017.1362728. Epub 2017 Oct 16.

3.

Aminomethyl-Derived Beta Secretase (BACE1) Inhibitors: Engaging Gly230 without an Anilide Functionality.

Butler CR, Ogilvie K, Martinez-Alsina L, Barreiro G, Beck EM, Nolan CE, Atchison K, Benvenuti E, Buzon L, Doran S, Gonzales C, Helal CJ, Hou X, Hsu MH, Johnson EF, Lapham K, Lanyon L, Parris K, O'Neill BT, Riddell D, Robshaw A, Vajdos F, Brodney MA.

J Med Chem. 2017 Jan 12;60(1):386-402. doi: 10.1021/acs.jmedchem.6b01451. Epub 2016 Dec 20.

4.

Enhancing antisense efficacy with multimers and multi-targeting oligonucleotides (MTOs) using cleavable linkers.

Subramanian RR, Wysk MA, Ogilvie KM, Bhat A, Kuang B, Rockel TD, Weber M, Uhlmann E, Krieg AM.

Nucleic Acids Res. 2015 Oct 30;43(19):9123-32. doi: 10.1093/nar/gkv992. Epub 2015 Oct 7.

5.

Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug-drug interactions with a novel series of centrally efficacious BACE1 inhibitors.

Brodney MA, Beck EM, Butler CR, Barreiro G, Johnson EF, Riddell D, Parris K, Nolan CE, Fan Y, Atchison K, Gonzales C, Robshaw AE, Doran SD, Bundesmann MW, Buzon L, Dutra J, Henegar K, LaChapelle E, Hou X, Rogers BN, Pandit J, Lira R, Martinez-Alsina L, Mikochik P, Murray JC, Ogilvie K, Price L, Sakya SM, Yu A, Zhang Y, O'Neill BT.

J Med Chem. 2015 Apr 9;58(7):3223-52. doi: 10.1021/acs.jmedchem.5b00191. Epub 2015 Apr 1.

6.

Discovery of a series of efficient, centrally efficacious BACE1 inhibitors through structure-based drug design.

Butler CR, Brodney MA, Beck EM, Barreiro G, Nolan CE, Pan F, Vajdos F, Parris K, Varghese AH, Helal CJ, Lira R, Doran SD, Riddell DR, Buzon LM, Dutra JK, Martinez-Alsina LA, Ogilvie K, Murray JC, Young JM, Atchison K, Robshaw A, Gonzales C, Wang J, Zhang Y, O'Neill BT.

J Med Chem. 2015 Mar 26;58(6):2678-702. doi: 10.1021/jm501833t. Epub 2015 Mar 9.

PMID:
25695670
7.

Preclinical PK/PD modeling and human efficacious dose projection for a glucokinase activator in the treatment of diabetes.

Zager MG, Kozminski K, Pascual B, Ogilvie KM, Sun S.

J Pharmacokinet Pharmacodyn. 2014 Apr;41(2):127-39. doi: 10.1007/s10928-014-9351-7. Epub 2014 Feb 28.

PMID:
24578187
8.

Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody.

Huang J, Ishino T, Chen G, Rolzin P, Osothprarop TF, Retting K, Li L, Jin P, Matin MJ, Huyghe B, Talukdar S, Bradshaw CW, Palanki M, Violand BN, Woodnutt G, Lappe RW, Ogilvie K, Levin N.

J Pharmacol Exp Ther. 2013 Aug;346(2):270-80. doi: 10.1124/jpet.113.204420. Epub 2013 May 29.

PMID:
23720456
9.

Activated CaMKII couples GluN2B and casein kinase 2 to control synaptic NMDA receptors.

Sanz-Clemente A, Gray JA, Ogilvie KA, Nicoll RA, Roche KW.

Cell Rep. 2013 Mar 28;3(3):607-14. doi: 10.1016/j.celrep.2013.02.011. Epub 2013 Mar 7.

10.

Stereoselective synthesis of spiropiperidines as BACE-1 aspartyl protease inhibitors via late stage N-arylation of a 1,8-diazaspiro[4.5]dec-3-en-2-one pharmacophore.

Lee CW, Lira R, Dutra J, Ogilvie K, O'Neill BT, Brodney M, Helal C, Young J, Lachapelle E, Sakya S, Murray JC.

J Org Chem. 2013 Mar 15;78(6):2661-9. doi: 10.1021/jo400016m. Epub 2013 Mar 4.

PMID:
23438191
11.

Spirocyclic sulfamides as β-secretase 1 (BACE-1) inhibitors for the treatment of Alzheimer's disease: utilization of structure based drug design, WaterMap, and CNS penetration studies to identify centrally efficacious inhibitors.

Brodney MA, Barreiro G, Ogilvie K, Hajos-Korcsok E, Murray J, Vajdos F, Ambroise C, Christoffersen C, Fisher K, Lanyon L, Liu J, Nolan CE, Withka JM, Borzilleri KA, Efremov I, Oborski CE, Varghese A, O'Neill BT.

J Med Chem. 2012 Nov 8;55(21):9224-39. doi: 10.1021/jm3009426. Epub 2012 Oct 8.

PMID:
22984865
12.

Demographic and contextual factors associated with inhalant use among youth in rural Alaska.

Driscoll DL, Dotterrer B, Collins D, Ogilvie K, Grube J, Johnson K.

Int J Circumpolar Health. 2012 Apr 16;71:1-4. doi: 10.3402/ijch.v71i0.18204.

13.

Discovery and characterization of an inhibitor of glucosylceramide synthase.

Richards S, Larson CJ, Koltun ES, Hanel A, Chan V, Nachtigall J, Harrison A, Aay N, Du H, Arcalas A, Galan A, Zhang J, Zhang W, Won KA, Tam D, Qian F, Wang T, Finn P, Ogilvie K, Rosen J, Aoyama R, Plonowski A, Cancilla B, Bentzien F, Yakes M, Mohan R, Lamb P, Nuss J, Kearney P.

J Med Chem. 2012 May 10;55(9):4322-35. doi: 10.1021/jm300122u. Epub 2012 Apr 19.

PMID:
22497444
14.

Neutralizing antibodies elicited by a novel detoxified pneumolysin derivative, PlyD1, provide protection against both pneumococcal infection and lung injury.

Salha D, Szeto J, Myers L, Claus C, Sheung A, Tang M, Ljutic B, Hanwell D, Ogilvie K, Ming M, Messham B, van den Dobbelsteen G, Hopfer R, Ochs MM, Gallichan S.

Infect Immun. 2012 Jun;80(6):2212-20. doi: 10.1128/IAI.06348-11. Epub 2012 Apr 2.

15.

A community prevention model to prevent children from inhaling and ingesting harmful legal products.

Johnson KW, Grube JW, Ogilvie KA, Collins D, Courser M, Dirks LG, Ogilvie D, Driscoll D.

Eval Program Plann. 2012 Feb;35(1):113-23. doi: 10.1016/j.evalprogplan.2011.08.001. Epub 2011 Aug 25.

16.

Discovery of a new class of glucosylceramide synthase inhibitors.

Koltun E, Richards S, Chan V, Nachtigall J, Du H, Noson K, Galan A, Aay N, Hanel A, Harrison A, Zhang J, Won KA, Tam D, Qian F, Wang T, Finn P, Ogilvie K, Rosen J, Mohan R, Larson C, Lamb P, Nuss J, Kearney P.

Bioorg Med Chem Lett. 2011 Nov 15;21(22):6773-7. doi: 10.1016/j.bmcl.2011.09.037. Epub 2011 Sep 17.

PMID:
21974949
17.

Combined directed ortho metalation-halogen dance (HD) synthetic strategies. HD-anionic ortho fries rearrangement and double HD sequences.

Miller RE, Rantanen T, Ogilvie KA, Groth U, Snieckus V.

Org Lett. 2010 May 21;12(10):2198-201. doi: 10.1021/ol100493v.

PMID:
20397661
18.

Studying implementation quality of a school-based prevention curriculum in frontier Alaska: application of video-recorded observations and expert panel judgment.

Johnson KW, Ogilvie KA, Collins DA, Shamblen SR, Dirks LG, Ringwalt CL, Norland JJ.

Prev Sci. 2010 Sep;11(3):275-86. doi: 10.1007/s11121-010-0174-5.

19.

Reducing adolescent use of harmful legal products: intermediate effects of a community prevention intervention.

Gruenewald PJ, Johnson K, Shamblen SR, Ogilvie KA, Collins D.

Subst Use Misuse. 2009;44(14):2080-98. doi: 10.3109/10826080902855223.

20.

The gift of time.

Ogilvie K.

CMAJ. 2009 Oct 13;181(8):E168. doi: 10.1503/cmaj.109-3047. No abstract available.

21.

Preventing youths' use of inhalants and other harmful legal products in frontier Alaskan communities: a randomized trial.

Johnson KW, Shamblen SR, Ogilvie KA, Collins D, Saylor B.

Prev Sci. 2009 Dec;10(4):298-312. doi: 10.1007/s11121-009-0132-2.

22.

Pharmacological characterization of a small molecule inhibitor of c-Jun kinase.

Cho H, Black SC, Looper D, Shi M, Kelly-Sullivan D, Timofeevski S, Siegel K, Yu XH, McDonnell SR, Chen P, Yie J, Ogilvie KM, Fraser J, Briscoe CP.

Am J Physiol Endocrinol Metab. 2008 Nov;295(5):E1142-51. doi: 10.1152/ajpendo.90298.2008. Epub 2008 Aug 26.

23.

Evaluating retailer behavior in preventing youth access to harmful legal products a feasibility test.

Courser MW, Holder HD, Collins D, Johnson K, Ogilvie KA.

Eval Rev. 2009 Oct;33(5):497-515. doi: 10.1177/0193841X08320940. Epub 2008 Jul 25.

24.

Changing community readiness to prevent the abuse of inhalants and other harmful legal products in Alaska.

Ogilvie KA, Moore RS, Ogilvie DC, Johnson KW, Collins DA, Shamblen SR.

J Community Health. 2008 Aug;33(4):248-58. doi: 10.1007/s10900-008-9087-7.

25.

The use of harmful legal products among pre-adolescent Alaskan students.

Saylor B, Fair M, Deike-Sims S, Johnson K, Ogilvie K, Collins D.

Int J Circumpolar Health. 2007 Dec;66(5):425-36.

26.

A community prevention intervention to reduce youth from inhaling and ingesting harmful legal products.

Johnson K, Holder H, Ogilvie K, Collins D, Ogilvie D, Saylor B, Courser M, Miller B, Moore R, Saltz B.

J Drug Educ. 2007;37(3):227-47.

27.

Antisense inhibition of 11betahydroxysteroid dehydrogenase type 1 improves diabetes in a novel cortisone-induced diabetic KK mouse model.

Bhat BG, Younis H, Herrera J, Palacio K, Pascual B, Hur G, Jessen B, Ogilvie KM, Rejto PA.

Biochem Biophys Res Commun. 2008 Jan 25;365(4):740-5. Epub 2007 Nov 20.

PMID:
18029262
28.

RAR and RXR modulation in cancer and metabolic disease.

Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR, Gronemeyer H.

Nat Rev Drug Discov. 2007 Oct;6(10):793-810. Review.

PMID:
17906642
29.

The case for Aboriginal Health Workers in palliative care.

McGrath PD, Patton MA, Ogilvie KF, Rayner RD, McGrath ZM, Holewa HA.

Aust Health Rev. 2007 Aug;31(3):430-9.

PMID:
17669066
30.
31.

Directed ortho metalation-boronation and Suzuki-Miyaura cross coupling of pyridine derivatives: a one-pot protocol to substituted azabiaryls.

Alessi M, Larkin AL, Ogilvie KA, Green LA, Lai S, Lopez S, Snieckus V.

J Org Chem. 2007 Mar 2;72(5):1588-94. Epub 2007 Feb 7.

PMID:
17284076
32.

Insights on Aboriginal peoples' views of cancer in Australia.

McGrath P, Holewa H, Ogilvie K, Rayner R, Patton MA.

Contemp Nurse. 2006 Sep;22(2):240-54.

PMID:
17026431
33.

Pyridine-2-propanoic acids: Discovery of dual PPARalpha/gamma agonists as antidiabetic agents.

Humphries PS, Almaden JV, Barnum SJ, Carlson TJ, Do QQ, Fraser JD, Hess M, Kim YH, Ogilvie KM, Sun S.

Bioorg Med Chem Lett. 2006 Dec 1;16(23):6116-9. Epub 2006 Sep 18.

PMID:
16979341
34.

Pyridine-3-propanoic acids: Discovery of dual PPARalpha/gamma agonists as antidiabetic agents.

Humphries PS, Bailey S, Almaden JV, Barnum SJ, Carlson TJ, Christie LC, Do QQ, Fraser JD, Hess M, Kellum J, Kim YH, McClellan GA, Ogilvie KM, Simmons BH, Skalitzky D, Sun S, Wilhite D, Zehnder LR.

Bioorg Med Chem Lett. 2006 Dec 1;16(23):6120-3. Epub 2006 Sep 14.

PMID:
16973358
35.

Biological characterization of a heterodimer-selective retinoid X receptor modulator: potential benefits for the treatment of type 2 diabetes.

Leibowitz MD, Ardecky RJ, Boehm MF, Broderick CL, Carfagna MA, Crombie DL, D'Arrigo J, Etgen GJ, Faul MM, Grese TA, Havel H, Hein NI, Heyman RA, Jolley D, Klausing K, Liu S, Mais DE, Mapes CM, Marschke KB, Michellys PY, Montrose-Rafizadeh C, Ogilvie KM, Pascual B, Rungta D, Tyhonas JS, Urcan MS, Wardlow M, Yumibe N, Reifel-Miller A.

Endocrinology. 2006 Feb;147(2):1044-53. Epub 2005 Nov 3.

PMID:
16269450
36.

The "right story" to the "right person": communication issues in end-of-life care for Indigenous people.

McGrath P, Ogilvie KF, Rayner RD, Holewa HF, Patton MA.

Aust Health Rev. 2005 Aug;29(3):306-16.

PMID:
16053435
37.

Conversion of human-selective PPARalpha agonists to human/mouse dual agonists: a molecular modeling analysis.

Wang M, Winneroski LL, Ardecky RJ, Babine RE, Brooks DA, Etgen GJ, Hutchison DR, Kauffman RF, Kunkel A, Mais DE, Montrose-Rafizadeh C, Ogilvie KM, Oldham BA, Peters MK, Rito CJ, Rungta DK, Tripp AE, Wilson SB, Xu Y, Zink RW, McCarthy JR.

Bioorg Med Chem Lett. 2004 Dec 20;14(24):6113-6.

PMID:
15546740
38.

Design and synthesis of alpha-aryloxy-alpha-methylhydrocinnamic acids: a novel class of dual peroxisome proliferator-activated receptor alpha/gamma agonists.

Xu Y, Rito CJ, Etgen GJ, Ardecky RJ, Bean JS, Bensch WR, Bosley JR, Broderick CL, Brooks DA, Dominianni SJ, Hahn PJ, Liu S, Mais DE, Montrose-Rafizadeh C, Ogilvie KM, Oldham BA, Peters M, Rungta DK, Shuker AJ, Stephenson GA, Tripp AE, Wilson SB, Winneroski LL, Zink R, Kauffman RF, McCarthy JR.

J Med Chem. 2004 May 6;47(10):2422-5.

PMID:
15115385
39.

Activation of the retinoid X receptor suppresses appetite in the rat.

Ogilvie KM, Saladin R, Nagy TR, Urcan MS, Heyman RA, Leibowitz MD.

Endocrinology. 2004 Feb;145(2):565-73. Epub 2003 Nov 6.

PMID:
14605005
40.

Design and synthesis of novel RXR-selective modulators with improved pharmacological profile.

Michellys PY, Boehm MF, Chen JH, Grese TA, Karanewsky DS, Leibowitz MD, Liu S, Mais DA, Mapes CM, Reifel-Miller A, Ogilvie KM, Rungta D, Thompson AW, Tyhonas JS, Yumibe N, Ardecky RJ.

Bioorg Med Chem Lett. 2003 Nov 17;13(22):4071-5.

PMID:
14592510
41.

Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids.

Michellys PY, Ardecky RJ, Chen JH, D'Arrigo J, Grese TA, Karanewsky DS, Leibowitz MD, Liu S, Mais DA, Mapes CM, Montrose-Rafizadeh C, Ogilvie KM, Reifel-Miller A, Rungta D, Thompson AW, Tyhonas JS, Boehm MF.

J Med Chem. 2003 Sep 11;46(19):4087-103.

PMID:
12954061
42.

Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.

Michellys PY, Ardecky RJ, Chen JH, Crombie DL, Etgen GJ, Faul MM, Faulkner AL, Grese TA, Heyman RA, Karanewsky DS, Klausing K, Leibowitz MD, Liu S, Mais DA, Mapes CM, Marschke KB, Reifel-Miller A, Ogilvie KM, Rungta D, Thompson AW, Tyhonas JS, Boehm MF.

J Med Chem. 2003 Jun 19;46(13):2683-96.

PMID:
12801232
43.

Mechanism of selective retinoid X receptor agonist-induced hypothyroidism in the rat.

Liu S, Ogilvie KM, Klausing K, Lawson MA, Jolley D, Li D, Bilakovics J, Pascual B, Hein N, Urcan M, Leibowitz MD.

Endocrinology. 2002 Aug;143(8):2880-5.

PMID:
12130551
44.

A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.

Etgen GJ, Oldham BA, Johnson WT, Broderick CL, Montrose CR, Brozinick JT, Misener EA, Bean JS, Bensch WR, Brooks DA, Shuker AJ, Rito CJ, McCarthy JR, Ardecky RJ, Tyhonas JS, Dana SL, Bilakovics JM, Paterniti JR Jr, Ogilvie KM, Liu S, Kauffman RF.

Diabetes. 2002 Apr;51(4):1083-7.

45.

Peroxisome proliferator-activated receptor subtype-specific regulation of hepatic and peripheral gene expression in the Zucker diabetic fatty rat.

Dana SL, Hoener PA, Bilakovics JM, Crombie DL, Ogilvie KM, Kauffman RF, Mukherjee R, Paterniti JR Jr.

Metabolism. 2001 Aug;50(8):963-71.

PMID:
11474486
46.

Metabolic effects of rexinoids: tissue-specific regulation of lipoprotein lipase activity.

Davies PJ, Berry SA, Shipley GL, Eckel RH, Hennuyer N, Crombie DL, Ogilvie KM, Peinado-Onsurbe J, Fievet C, Leibowitz MD, Heyman RA, Auwerx J.

Mol Pharmacol. 2001 Feb;59(2):170-6.

PMID:
11160850
47.
48.

Mechanisms mediating the influence of alcohol on the hypothalamic-pituitary-adrenal axis responses to immune and nonimmune signals.

Ogilvie K, Lee S, Weiss B, Rivier C.

Alcohol Clin Exp Res. 1998 Aug;22(5 Suppl):243S-247S. Review.

PMID:
9727644

Supplemental Content

Loading ...
Support Center